Tofacitinib is beneficial for patients who have not responded well to traditional disease-modifying antirheumatic drugs (DMARDs). It may be prescribed alone or in combination with other DMARDs, excluding biologics and certain potent immunosuppressants due to the risk of serious infection.

Dosage: Typically, the dosage is 5 mg twice daily, but the exact dosage should be prescribed by a healthcare provider based on medical condition and treatment response.

Administration: Tofacitinib should be taken orally with or without food.

Consistency: For best results, take it at the same times each day to maintain an even level of medication in your body.

Monitoring: Regular monitoring by a healthcare provider is essential to assess effectiveness and watch for potential side effects, including blood work to check blood cell counts, kidney function, and liver enzymes.

Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, Kishore N. Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. Journal of Pharmacology and Experimental Therapeutics. 2014 Jan 1;348(1):165-73.

Scott LJ. Tofacitinib: a review of its use in adult patients with rheumatoid arthritis. Drugs. 2013 Jun;73:857-74.

Tran V, Shammas RM, Sauk JS, Padua D. Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy. Clinical and experimental gastroenterology. 2019 May 2:179-91.